6,7-Dimethoxy-1-tert-butyl-isochinolin | 4029-11-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 6,7-Dimethoxy-1-tert-butyl-isochinolin
• 英文别名: 1-tert-butyl-6,7-dimethoxy-isoquinoline；1-Tert-butyl-6,7-dimethoxyisoquinoline
• CAS: 4029-11-2
• 化学式: C₁₅H₁₉NO₂
• 分子量: 245.321
• InChiKey: XXHMRKNQPXXXPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS
  申请人：Goff Dane

  公开号：US20080188474A1

  公开（公告）日：2008-08-07

  Substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

  本发明揭示了替代三唑和含有该化合物的制药组合物，其在抑制受体蛋白酪氨酸激酶Axl的活性方面是有用的。还揭示了使用该化合物治疗与Axl活性相关的疾病或病况的方法。
• Substituted triazoles useful as Axl inhibitors
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US10166216B2

  公开（公告）日：2019-01-01

  Substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

  所公开的取代三唑类化合物和含有这些化合物的药物组合物有助于抑制受体蛋白酪氨酸激酶 Axl 的活性。还公开了使用这些化合物治疗与 Axl 活性相关的疾病或病症的方法。
• ENPP1 Inhibitors and Their Use for the Treatment of Cancer
  申请人：THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

  公开号：US20210369747A1

  公开（公告）日：2021-12-02

  Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.
• US8906922B2
  申请人：——

  公开号：US8906922B2

  公开（公告）日：2014-12-09